Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

French drugmaker Sanofi to cut up to 1,680 jobs in Europe

share with twitter share with LinkedIn share with facebook
06/26/2020 | 12:37pm EDT
FILE PHOTO: Sanofi logo is seen in Paris

By Matthias Blamont

French drugmaker Sanofi, which employs more than 100,000 people worldwide, confirmed on Friday it will axe up to 1,680 jobs in Europe to cut costs and lift profits.

The lay-offs are part of a broader strategy outlined in December by Sanofi CEO Paul Hudson, which includes a cost savings target of 2 billion euros ($2.2 billion) by 2022.

A Sanofi spokeswoman said the cuts, mainly affecting blue-collar workers, would be carried out over three years.

Reuters reported on Thursday that Sanofi was considering hundreds of job cuts and would hold talks with staff representatives on Friday and on June 29.

A source said some 1,000 jobs would go in France, where it has about 25,000 staff.

None of Sanofi's plants will close, a source familiar with its thinking said, but activity at some research centres will cease after it decided last year to end diabetes and cardiovascular research, two areas where it has lost ground.

An internal document seen by Reuters said Sanofi will focus on greater efficiency through digitalisation and IT outsourcing.

A French Finance Ministry source told Reuters that the government will ensure that there are no sites closed and there are no forced lay-offs.

Sanofi has been bulking up in areas where it believes it can secure leading positions, including cancer drugs and last year said it would buy U.S. biotechnology firm Synthorx for about $2.5 billion.

Vaccines are also a priority for Sanofi which is working on two candidates to prevent COVID-19, one with GlaxoSmithKline and another with U.S. Translate Bio.

Sanofi said last week it would invest 610 million euros at two French sites to turn them into a hub dedicated to research, development and production of vaccines. Some 200 new jobs are expected to be created at one of the locations.

"Today's news is hard to digest," Thierry Bodin, an official with the CGT union said.

(Reporting by Matthias Blamont; Additional reporting by Gwenaelle Barzic; Writing by Josephine Mason and Matthieu Protard; Editing by Jan Harvey, Mark Potter and Alexander Smith)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -0.34% 1642.6 Delayed Quote.-7.23%
SANOFI SA -0.13% 93.4 Real-time Quote.4.52%
TRANSLATE BIO, INC. -2.26% 18.4 Delayed Quote.133.29%
share with twitter share with LinkedIn share with facebook
07:40aGLAXOSMITHKLINE : Goldman Sachs keeps its Buy rating
07/15GLAXOSMITHKLINE : Orchard in License Agreements for Stable Cell Line Technology ..
07/15GLAXOSMITHKLINE : ViiV Healthcare announces superior efficacy of investigational..
07/15GLAXOSMITHKLINE : Goldman Sachs maintains a Buy rating
07/15GLAXOSMITHKLINE : JP Morgan sticks Neutral
07/15GLAXOSMITHKLINE : Belantamab Mafodotin Gets Recommendation From FDA Panel
07/14GLAXOSMITHKLINE : GSK announces FDA advisory committee votes in favour of positi..
07/14GLAXOSMITHKLINE : FDA panel votes in favor of approving GSK's multiple myeloma d..
07/14Electromedical Technologies Q1 Revenues Increase 22%; Innovative DeepPulse(TM..
07/10GLAXOSMITHKLINE : FDA unclear if benefits of GSK multiple myeloma drug outweigh ..
More news
Sales 2020 35 274 M 44 277 M 44 277 M
Net income 2020 4 436 M 5 568 M 5 568 M
Net Debt 2020 23 087 M 28 980 M 28 980 M
P/E ratio 2020 16,3x
Yield 2020 4,85%
Capitalization 82 137 M 104 B 103 B
EV / Sales 2019
EV / Sales 2020 2,98x
Nbr of Employees 99 437
Free-Float 91,2%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 1 890,78 GBX
Last Close Price 1 650,40 GBX
Spread / Highest target 39,4%
Spread / Average Target 14,6%
Spread / Lowest Target -6,87%
EPS Revisions
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.64%390 605
ROCHE HOLDING AG8.01%305 807
MERCK & CO., INC.-12.66%200 515
PFIZER, INC.-10.08%198 419
NOVARTIS AG-9.65%193 847